Vernalis' collaboration with Tris

Latest status of the programmes for the US prescription market.

Explore Commercial Pipeline

Tuzistra® XR, the first cough cold product resulting from a development and licensing deal with Tris Pharma Inc., was approved by the FDA in April 2015. Vernalis has 4 additional products in development in its cough cold pipeline.


Read more: Cough cold

In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older and re-launched the product in Q4 2016.

Read more: Moxatag®

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or